Tag:

Amgen

Latest Headlines

Latest Headlines

Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus

Amgen CEO Robert Bradway nabbed Onyx Pharmaceuticals for $10.4 billion last summer, but that wasn't enough to net him the kind of deal-related bonus some of his peers enjoy. But his take-home increased over last year's haul, which was enough to score him 13th place on the list of biopharma's highest-paid chiefs.

Amgen's closely watched melanoma prospect misses PhIII survival endpoint

Amgen's cancer-fighting viral vaccine has been rolling through Phase III, producing a series of positive results. But after missing a secondary endpoint in overall survival, the California-based biotech's hot prospect now has a big blot on its resume.

Amgen, GSK part on fast-selling Prolia, mostly

GlaxoSmithKline and Amgen are parting ways on Prolia, their comarketed osteoporosis med that's been among the fastest-growing products approved in the last few years. Amgen will take over the task in most areas under their agreement, leaving GSK freer to buckle down on some new launches of its own.

Amgen's viral cancer vaccine misses its survival goal in melanoma PhIII

After a string of promising late-stage results, Amgen's cancer-fighting viral vaccine failed to extend patients' lives at a statistically significant rate, missing a secondary endpoint and marking the first blemish on the biotech's top cancer prospect.

Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol

Thanks to genomic sequencing, some heart-healthy mutants and billions of dollars spent on R&D, rival drug developers are bearing down on a promising new way of treating the scourge of high cholesterol. And with the first FDA applications likely coming in the next year, the nascent field's trailblazers are vying for the top spot with blockbuster aspirations.

Amgen's PCSK9 drug slashes 'bad' cholesterol in PhIII, stoking blockbuster hopes

Amgen widened its lead among competing drugmakers in a promising new field of cardio treatments on the strength of late-stage results in which its in-development drug lowered LDL cholesterol by as much as 75%.

NeuroSigma brings on two Amgen execs to bolster its finance team

Two Amgen executives are heading to devicemaker NeuroSigma to join the finance team there as the company gears up for commercialization of its big product. NeuroSigma, which specializes in devices for neurological and neuropsychiatric disorders, appointed Carl Adams to be its chief financial officer and Craig Rostamian as its vice president of finance, overseeing planning and analysis, according to a company release.

Amgen posts positive PhIII data as judgment day for cancer vaccine bet nears

In 2011, Amgen splashed out an initial $425 million to buy BioVex and its cancer vaccine in what analysts described as a "high risk, high reward" deal. A little more than three years later Amgen is close to finding out if the bet has paid off, and the latest data is encouraging.

Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster

Amgen's promising cardio drug aced its 6th late-stage study, the company said, beating out statins in patients with a cholesterol-boosting genetic disorder and widening the drugmaker's lead in a potentially lucrative new field.

Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII

A new round of late-stage data on Amgen's cancer-fighting viral vaccine talimogene laherparepvec, better known as T-Vec, found that about two-thirds of the tumors injected with T-Vec shrank 50% or more. And the same effect was seen in about a third of all uninjected tumors in the skin and lymph nodes, providing an indication that the treatment is triggering the desired immune system effect.